Research and Clinical Trials

Title  
ImmunoGen IMGN853-0403: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator?s Choice of Chemotherapy in Women with Folate Receptor á-Positive Advanced Epithelial Ovarian
Brief Description  
To compare the objective response rate (ORR) of patients with EOC, primary peritoneal cancer and Fallopian tube cancer randomized to IMGN853 or selected standard of care chemotherapy
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Ovary
Status  
OPEN
Start Date  
05/18/2017
IRB Number  
00020082
Principal Investigator  
Crane, Erin King
Contact Name  
Kelly D Bumgarner

For More Information, Contact  Kelly  D, Bumgarner
Phone:  704-403-2520 Fax:    
Email:  Kelly.Bumgarner@carolinashealthcare.org
Address:100 Medical Park Drive Suite 110 Concord, NC 28025
Close